Therapure Biopharma to sell CDMO business to 3SBio

05:13 EDT 4 Sep 2017 | Pharmaceutical Business Review

Canada-based Therapure Biopharma has agreed to divest its contract development and manufacturing (CDMO) business to a joint venture between Chinese biotechnology company 3SBio and CPE Funds for $290m.

Original Article: Therapure Biopharma to sell CDMO business to 3SBio


More From BioPortfolio on "Therapure Biopharma to sell CDMO business to 3SBio"

Quick Search

Relevant Topics

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...